rite aid no longer filling glp 1 prescriptions Closure in Honesdale Raises Concerns Over Growth of Pharmacy Deserts Rite Aid still filling prescriptions

Lilly has another candidate further ahead in development outside China that is taking up more of its R&D investment, namely retatrutide, a triple-acting agent that targets GLP-1, GIP, and glucagon in one molecule and is in several phase 3 trials across weight loss, diabetes, obstructive sleep apnoea, osteoarthritis, and chronic lower back pain, as well as for reducing the risk of cardiovascular and kidney complications in people with obesity

doi: 10.1016/j.gde.2009.10.009 308 SethR

1,8-cineole ameliorates diabetic retinopathy by inhibiting retinal pigment epithelium ferroptosis via ppar-/txnip pathways

This is unusual for such a rare condition

For most patients without severe malabsorption, sublingual B12 is a reasonable and convenient alternative to injections

Oxidative and nitrosative stress markers in obsessive-compulsive disorder: A systematic review and meta-analysis